Risk factors indicating the need for surgical therapy in patients with pyogenic liver abscesses.
Abdominal infections
Hepatic artery thrombosis
Klebsiella pneumoniae infection
Liver abscess
Liver transplantation
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
21 Feb 2023
21 Feb 2023
Historique:
received:
04
05
2022
accepted:
13
02
2023
entrez:
22
2
2023
pubmed:
23
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Percutaneous drainage (PD) and antibiotics are the therapy of choice (non-surgical therapy [non-ST]) for pyogenic liver abscesses (PLA), reserving surgical therapy (ST) for PD failure. The aim of this retrospective study was to identify risk factors that indicate the need for ST. We reviewed the medical charts of all of our institution's adult patients with a diagnosis of PLA between January 2000 and November 2020. A series of 296 patients with PLA was divided into two groups according to the therapy used: ST (n = 41 patients) and non-ST (n = 255). A comparison between groups was performed. The overall median age was 68 years. Demographics, clinical history, underlying pathology, and laboratory variables were similar in both groups, except for the duration of PLA symptoms < 10 days and leukocyte count which were significantly higher in the ST group. The in-hospital mortality rate in the ST group was 12.2% vs. 10.2% in the non-ST group (p = 0.783), with biliary sepsis and tumor-related abscesses as the most frequent causes of death. Hospital stay and PLA recurrence were statistically insignificant between groups. One-year actuarial patient survival was 80.2% in the ST group vs. 84.6% in the non-ST (p = 0.625) group. The presence of underlying biliary disease, intra-abdominal tumor, and duration of symptoms for less than 10 days on presentation comprised the risk factors that indicated the need to perform ST. There is little evidence regarding the decision to perform ST, but according to this study, the presence of underlying biliary disease or an intra-abdominal tumor and the duration of PLA symptoms < 10 days upon presentation are risk factors that should sway the surgeons to perform ST instead of PD.
Sections du résumé
BACKGROUND
BACKGROUND
Percutaneous drainage (PD) and antibiotics are the therapy of choice (non-surgical therapy [non-ST]) for pyogenic liver abscesses (PLA), reserving surgical therapy (ST) for PD failure. The aim of this retrospective study was to identify risk factors that indicate the need for ST.
METHODS
METHODS
We reviewed the medical charts of all of our institution's adult patients with a diagnosis of PLA between January 2000 and November 2020. A series of 296 patients with PLA was divided into two groups according to the therapy used: ST (n = 41 patients) and non-ST (n = 255). A comparison between groups was performed.
RESULTS
RESULTS
The overall median age was 68 years. Demographics, clinical history, underlying pathology, and laboratory variables were similar in both groups, except for the duration of PLA symptoms < 10 days and leukocyte count which were significantly higher in the ST group. The in-hospital mortality rate in the ST group was 12.2% vs. 10.2% in the non-ST group (p = 0.783), with biliary sepsis and tumor-related abscesses as the most frequent causes of death. Hospital stay and PLA recurrence were statistically insignificant between groups. One-year actuarial patient survival was 80.2% in the ST group vs. 84.6% in the non-ST (p = 0.625) group. The presence of underlying biliary disease, intra-abdominal tumor, and duration of symptoms for less than 10 days on presentation comprised the risk factors that indicated the need to perform ST.
CONCLUSIONS
CONCLUSIONS
There is little evidence regarding the decision to perform ST, but according to this study, the presence of underlying biliary disease or an intra-abdominal tumor and the duration of PLA symptoms < 10 days upon presentation are risk factors that should sway the surgeons to perform ST instead of PD.
Identifiants
pubmed: 36808482
doi: 10.1007/s00423-023-02837-0
pii: 10.1007/s00423-023-02837-0
pmc: PMC9942623
doi:
Substances chimiques
Anti-Bacterial Agents
0
Polyesters
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
BMC Infect Dis. 2021 Feb 11;21(1):171
pubmed: 33573593
HPB (Oxford). 2018 Jul;20(7):583-590
pubmed: 29496466
World J Gastroenterol. 2008 Feb 7;14(5):747-51
pubmed: 18205266
Ann Surg. 2005 Mar;241(3):485-90
pubmed: 15729072
Am J Gastroenterol. 2010 Jan;105(1):117-24
pubmed: 19888200
Dig Liver Dis. 2008 Aug;40(8):697-8
pubmed: 18373965
J Am Coll Surg. 1994 Dec;179(6):727-32
pubmed: 7952485
J Am Coll Surg. 2010 Jun;210(6):975-83
pubmed: 20510807
Front Med (Lausanne). 2021 May 12;8:675345
pubmed: 34055845
J Clin Exp Hepatol. 2021 May-Jun;11(3):312-320
pubmed: 33994714
Am J Trop Med Hyg. 2016 Sep 7;95(3):683-8
pubmed: 27325801
World J Surg. 1994 Nov-Dec;18(6):852-7; discussion 858
pubmed: 7846908
Clin Radiol. 2017 Aug;72(8):692.e9-692.e15
pubmed: 28364952
HPB Surg. 2012;2012:316013
pubmed: 22536008
Mayo Clin Proc Innov Qual Outcomes. 2018 Feb 22;2(1):16-25
pubmed: 30225428
Am J Surg. 2002 Feb;183(2):205-8
pubmed: 11918890
J Hepatobiliary Pancreat Sci. 2015 Feb;22(2):156-65
pubmed: 25339111
Ann Surg. 1990 Dec;212(6):655-62
pubmed: 2256756
World J Surg. 1991 May-Jun;15(3):372-6; discussion 376-7
pubmed: 1853616
BMC Infect Dis. 2020 Feb 17;20(1):145
pubmed: 32066406
Transpl Infect Dis. 2020 Dec;22(6):e13360
pubmed: 32515881
Am J Gastroenterol. 2005 Feb;100(2):322-31
pubmed: 15667489
Liver Int. 2021 Apr;41(4):810-818
pubmed: 33314531
Arch Surg. 1998 Mar;133(3):242-5
pubmed: 9517733
World J Gastroenterol. 2012 Jun 21;18(23):2948-55
pubmed: 22736918
HPB (Oxford). 2003;5(2):91-5
pubmed: 18332963
BMC Infect Dis. 2013 Jan 30;13:56
pubmed: 23363608
J Trauma. 2009 Mar;66(3):621-7; discussion 627-9
pubmed: 19276729
Aliment Pharmacol Ther. 2005 May 15;21(10):1185-8
pubmed: 15882238
Am J Surg. 2001 Feb;181(2):177-86
pubmed: 11425062
J Vasc Interv Radiol. 2009 Aug;20(8):1059-65
pubmed: 19560374
Eur J Gastroenterol Hepatol. 2011 Sep;23(9):770-7
pubmed: 21716118
Dig Liver Dis. 2008 Aug;40(8):690-6
pubmed: 18337194
J Visc Surg. 2015 Sep;152(4):231-43
pubmed: 25770745
World J Surg. 2018 Oct;42(10):3341-3349
pubmed: 29633100
Am J Surg. 2013 Jan;205(1):52-7
pubmed: 22794706
HPB (Oxford). 2017 Oct;19(10):889-893
pubmed: 28693978
Surgery. 2016 May;159(5):1316-24
pubmed: 26775071
BMC Infect Dis. 2021 Jun 23;21(1):597
pubmed: 34157983
Dig Dis Sci. 2020 May;65(5):1529-1538
pubmed: 31559551
Emerg Infect Dis. 2008 Oct;14(10):1592-600
pubmed: 18826824
Dig Liver Dis. 2014 Sep;46(9):813-7
pubmed: 24881853
J Microbiol Immunol Infect. 2016 Oct;49(5):646-653
pubmed: 25442876
Int Surg. 1997 Jan-Mar;82(1):98-101
pubmed: 9189815
AJR Am J Roentgenol. 2017 Jul;209(1):205-213
pubmed: 28504550
J Gastrointest Surg. 2014 May;18(5):922-8
pubmed: 24510300
Gastroenterol Clin North Am. 2020 Jun;49(2):361-377
pubmed: 32389368
Am J Surg. 1991 Jan;161(1):76-82; discussion 82-3
pubmed: 1987861